Effect of carboplatin on malondialdehyde as a marker of lipoderoxidation in the submandibular gland of rats

Authors

  • E Bachmeier Universidad Nacional de Córdoba, Fac Odontología

Keywords:

Witar rats, carboplatin, malondialdehyde, submandibular gland

Abstract

The objective of the present work was to evaluate the effect of carboplatin (Cp) on submandibular gland homogenate of Wistar rats through the determination of malondialdehyde levels, as the main end product of lipoperoxidation, in an experimental model. Sixteen three-month-old male Wistar rats were used, housed in individual cages, with controlled temperature and lighting and free diet. A completely randomized design was used and two experimental groups were established: 1) Control (C), administering an intraperitoneal dose of saline solution for one day, n: 8, 2) Animals treated with carboplatin (Cp) applying a dose i.p. of 100 mg / Kg of body weight for one day, n: 8. The animals were fasted for 24 hours and subsequently anesthetized. Then both submandibular glands were removed. Malondialdehyde levels were analyzed in submandibular gland homogenate in both experimental groups. Variations between the groups analyzed were evaluated using the Student's t test for paired samples, setting a p-value <0.05 for statistical significance. Project approved by CICUAL. Faculty of Medical Sciences (UNC). The group of Rats C o showed a concentration of 7.32 ± 0.48 µmol / mg of gland. The Cp group had a concentration of 12.57 ± 0.71 µmol / mg of gland, expressing a significant decrease compared to the control group p <0.0006. Cp at the dose tested would cause a decrease in lipoperoxidation in the submandibular gland of rats. Possibly the glandular antioxidant battery would neutralize the oxidative stress of acinar cells. These results suggest a future evaluation of superoxide dismutase (SOD) activity and uric acid (UA) levels

References

1. Zhang Y, Zhang R. Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs. Drug Test Anal. 2018; 10(1):81-94. doi: 10.1002/dta.2290.

2. Plumridge RJ, Sewell GJ. Dose-banding of cytotoxic drugs: a new concept in cancer chemotherapy. Am J Health Syst Pharm. 2001;58(18):1760-4. doi: 10.1093/ajhp/58.18.1760.

3. Veal GJ, Errington J, Hayden J, Hobin D, Murphy D, Dommett RM, Tweddle DA, Jenkinson H, Picton S. Carboplatin therapeutic monitoring in preterm and full-term neonates. Eur J Cancer. 2015; 51(14):2022-30. doi: 10.1016/j.ejca.2015.07.011.

4. Veal GJ, Cole M, Errington J, Pearson AD, Gerrard M, Whyman G, Ellershaw C, Boddy AV. Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. Cancer Chemother Pharmacol. 2010 May;65(6):1057-66. doi: 10.1007/s00280-009-1111-9.

5. Yamamoto R, Kaneuchi M, Nishiya M, Todo Y, Takeda M, Okamoto K, Negishi H, Sakuragi N, Fujimoto S, Hirano T. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer. Cancer Chemother Pharmacol. 2002 Aug; 50(2):137-42. doi: 10.1007/s00280-002-0471-1.

6. Suzuki K, Matsumoto K, Hashimoto K, Kurokawa K, Jinbo S, Suzuki T, Imai K, Yamanaka H, Kawashima K, Takahashi H. Carboplatin-based combination chemotherapy for testicular cancer: relationship among administration dose of carboplatin, renal function and myelosuppression. Hinyokika Kiyo. 1995;41(10):775-80.

7. Xiang M, Colevas AD, Holsinger FC, Le QX, Beadle BM. Survival After Definitive Chemoradiotherapy With Concurrent Cisplatin or Carboplatin for Head and Neck Cancer. J Natl Compr Canc Netw. 2019;17(9):1065-1073. doi: 10.6004/jnccn.2019.7297.

8. Grasse S, Lienhard M, Frese S, Kerick M, Steinbach A, Grimm C, Hussong M, et al. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance. Genome Med. 2018; 10(1):55. doi: 10.1186/s13073-018-0562-1.

9. Bisch SP, Sugimoto A, Prefontaine M, Bertrand M, Gawlik C, Welch S, McGee J. Treatment Tolerance and Side Effects of Intraperitoneal Carboplatin and Dose-Dense Intravenous Paclitaxel in Ovarian Cancer. J Obstet Gynaecol Can. 2018; 40(10):1283-1287.e1. doi: 10.1016/j.jogc.2018.01.028.

10. Alberti P. Platinum-drugs induced peripheral neurotoxicity: clinical course and preclinical evidence. Expert Opin Drug Metab Toxicol. 2019;15(6):487-497. doi: 10.1080/17425255.2019.1622679.

11. Epstein JB, Schubert MM. Oropharyngeal mucositis in cancer therapy. Review of pathogenesis, diagnosis, and management. Oncology (Williston Park). 2003;17(12):1767-79.

12. Santos RC, Dias RS, Giordani AJ, Segreto RA, Segreto HR. Mucosite em pacientes portadores de câncer de cabeça e pescoço submetidos à radioquimioterapia [Mucositis in head and neck cancer patients undergoing radiochemotherapy]. Rev Esc Enferm USP. 2011; 45(6):1338-44. Portuguese. doi: 10.1590/s0080-62342011000600009.

13. Nishijima S, Yanase T, Tsuneki I, Tamura M, Kurabayashi T. Examination of the taste disorder associated with gynecological cancer chemotherapy. Gynecol Oncol. 2013;131(3):674-8. doi: 10.1016/j.ygyno.2013.09.015.

14. Peyrot des Gachons C, Breslin PA. Salivary Amylase: Digestion and Metabolic Syndrome. Curr Diab Rep. 2016; 16(10):102. doi: 10.1007/s11892-016-0794-7.

15. de Paula F, Teshima THN, Hsieh R, Souza MM, Nico MMS, Lourenco SV. Overview of Human Salivary Glands: Highlights of Morphology and Developing Processes. Anat Rec (Hoboken). 2017; 300(7):1180-1188. doi: 10.1002/ar.23569.

16. Scarpace SL, Brodzik FA, Mehdi S, Belgam R. Treatment of head and neck cancers: issues for clinical pharmacists. Pharmacotherapy. 2009; 29(5):578-92. doi: 10.1592/phco.29.5.578.

17. de Castro G Jr, Guindalini RS. Supportive care in head and neck oncology. Curr Opin Oncol. 2010; 22(3):221-5. doi: 10.1097/CCO.0b013e32833818ff.

18. Fagundes NC, Fernandes LM, Paraense RS, de Farias-Junior PM, Teixeira FB, Alves-Junior SM, Pinheiro Jde J, Crespo-López ME, Maia CS, Lima RR. Binge Drinking of Ethanol during Adolescence Induces Oxidative Damage and Morphological Changes in Salivary Glands of Female Rats. Oxid Med Cell Longev. 2016; 2016:7323627. doi: 10.1155/2016/7323627.

19. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol. 1990; 186:407-21. doi: 10.1016/0076-6879(90)86134-h.

20. Bittencourt LO, Puty B, Charone S, Aragão WAB, Farias-Junior PM, Silva MCF, Crespo-Lopez ME, Leite AL, Buzalaf MAR, Lima RR. Oxidative Biochemistry Disbalance and Changes on Proteomic Profile in Salivary Glands of Rats Induced by Chronic Exposure to Methylmercury. Oxid Med Cell Longev. 2017; 2017:5653291. doi: 10.1155/2017/5653291.

21. Ito K, Morikawa M, Inenaga K. The effect of food consistency and dehydration on reflex parotid and submandibular salivary secretion in conscious rats. Arch Oral Biol. 2001;46(4):353-63. doi: 10.1016/s0003-9969(00)00124-2. PMID: 11269869.

22. Bachmeier E, Mazzeo MA, López MM, Linares JA, Jarchum G, Wietz FM, Finkelberg AB. Mucositis and salivary antioxidants in patients undergoing bone marrow transplantation (BMT). Med Oral Patol Oral Cir Bucal. 2014; 19(5):e444-50. doi: 10.4317/medoral.19062.

23. Gallia MC, Bachmeier E, Ferrari A, Queralt I, Mazzeo MA, Bongiovanni GA. Pehuén (Araucaria araucana) seed residues are a valuable source of natural antioxidants with nutraceutical, chemoprotective and metal corrosion-inhibiting properties. Bioorg Chem. 2020; 104:104175. doi: 10.1016/j.bioorg.2020.104175.

24. Dawes C, Pedersen AM, Villa A, Ekström J, Proctor GB, Vissink A, Aframian D, McGowan R, Aliko A, Narayana N, Sia YW, Joshi RK, Jensen SB, Kerr AR, Wolff A. The functions of human saliva: A review sponsored by the World Workshop on Oral Medicine VI. Arch Oral Biol. 2015; 60(6):863-74. doi: 10.1016/j.archoralbio.2015.03.004.

Downloads

Published

2021-08-03

Issue

Vol. 31 No. 2 (2021): Rev Fac Odont 31(2)-2021-Agosto

Section

RESEARCH

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:

  1. Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros:
    • La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia
  2. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
  3. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) después del su publicación en la revista, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).